Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral anticoagulant, Savaysa (edoxaban), for the treatment of DVT and PE, as well as for atrial fibrillation. The FDA press release is here (link). Savaysa is the 4th of the NOACS now approved for VTE treatment. This table summarizes the differences, advantages and disadvantages comparing the 4 drugs. The detailed drug package insert with dosing information is here (link).
For the management of acute venous thromboembolism, Savaysa has the disadvantage compared to Xarelto and Eliquis that it should not be used immediately upon making a diagnosis of VTE, but only after 5-10 days of treatment with a parenteral anticoagulant (based on the Savaysa phase 3 clinical trial design and the FDA approval language). That would make treatment of acute VTE with Savaysa significantly more cumbersome than with Xarelto or Eliquis.
Disclosures: I have consulted in the past for Daiichi, Janssen and Boehringer-Ingelheim.
Last updated: Jan 9th, 2015